Reference - Detail
| RRC ID | 82450 |
|---|---|
| Author | Sasaki M, Kato D, Yoshida H, Shimizu T, Ogiwara H. |
| Title | Efficacy of CBP/p300 Dual Inhibitors against De-repression of KREMEN2 in cBAF-Deficient Cancers. |
| Journal | Cancer Res Commun |
| Abstract |
The SWI/SNF chromatin remodeling complex is divided into three subcomplexes: cBAF, PBAF, and ncBAF. Constituent genes (e.g., SMARCB1, SMARCA4, SMARCA2, and SS18) of the SWI/SNF complex often harbor genetic abnormalities in various cancers. Previously, we found that histone acetyltransferases CBP/p300 dual inhibitors could be promising treatments for SMARCB1-deficient cancers. We show that treatment with CBP/p300 dual inhibitors causes synthetic lethality in cBAF-deficient cancers such as SMARCA4/SMARCA2-deficient and SS18-SSX fusion cancers. Given the sensitivity to CBP/p300 dual inhibitors and their commonality with SWI/SNF subcomplexes containing each subunit, CBP/p300 dual inhibitors could be promising treatments for cancers harboring abnormalities in constituent genes included in the entire cBAF subcomplex. Since SMARCA4/SMARCA2-deficient and SS18-SSX fusion cancer cells depend on transcriptional upregulation of KREMEN2 due to SMARCA4/SMARCA2-deficiency and SS18-SSX fusion, we clarified that synthetic lethality is induced by repressing expression of KREMEN2 by simultaneous inhibition of CBP/p300. In addition, simultaneous inhibition of CBP/p300 led to transcriptional downregulation of KREMEN2, followed by apoptosis induction via KREMEN1. Furthermore, treatment with CBP/p300 dual inhibitor suppressed the growth of xenografts derived from SMARCA4/SMARCA2-deficient and SS18-SSX fusion cancer cells, resulting from repression of KREMEN2 and induction of apoptosis. Thus, CBP/p300 dual inhibitors could be promising for SMARCA4/SMARCA2-deficient lung cancer and SS18-SSX fusion synovial sarcoma, which are entirely deficient in the cBAF complex. |
| Published | 2024-12-3 |
| DOI | 10.1158/2767-9764.CRC-24-0484 |
| PII | 750389 |
| PMID | 39625239 |
| Altmetric score |
オルトメトリクス指標項目
|
| The most frequently cited source | X(Twitter) |
| Total number of mentions | 6 |
| Altmetric score changes over past 6months | 0.0 |
| Resource | |
| Human and Animal Cells | Aska-SS(RCB3576) HS-SY-II(RCB2231) OS-RC-2(RCB0735) |